BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75 [Reuters]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Reuters
BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75 | Reuters Reuters Staff 1 Min Read Feb 22 (Reuters) - Sage Therapeutics Inc: * SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE * ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING * ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR BREXANOLONE FOR POSTPARTUM DEPRESSION IN 1H 2018 FOLLOWING PRE-NDA MEETING * QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $1.75 * CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES AS OF DEC 31, 2017 WERE $518.8 MILLION, VERSUS $397.5 MILLION AT DECEMBER 31, 2016 * EXPECTS OPERATING EXPENSES TO INCREASE YEAR OVER YEAR IN 2018 * Q4 EARNINGS PER SHARE VIEW $-1.99 -- THOMSON REUTERS I/B/E/S * SAGE -EXPECTS EXISTING CASH,CASH EQUIVALENTS, MARKETABLE SECURITIES, OTHER SALES TO ENABLE CO TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO 2020 Source text for Eikon: Further company coverage: A
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $34.00 to $19.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $25.00 to $17.00. They now have a "market perform" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
SAGE
Earnings
- 2/14/24 - Beat
SAGE
Sec Filings
- 4/17/24 - Form 8-K
- 3/27/24 - Form SC
- 3/26/24 - Form 8-K
- SAGE's page on the SEC website